Constructs for delivery of therapeutic agents to neuronal cells
View Patent ↗A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H N domain of a clostridial toxin and is not a fragment or derivative of a H N domain of a clostridial toxin.
1. A composition comprising a therapeutic agent linked to a delivery polypeptide, SEQ ID NO. 12, wherein the delivery polypeptide is for delivery of a therapeutic agent to a neuronal cell, said delivery polypeptide comprising:
a binding domain that binds to the neuronal cell and comprises a hybrid of a botulinum H C domian and a tetanus H C domain, and
a translocation domain comprising an H N domain of a diphtheria toxin that translocates the therapeutic agent into the neuronal cell,
wherein the delivery polypeptide has the binding specificity of tetanus toxin and reduced affinity to neutralizing antibodies to tetanus toxin compared with the affinity to such antibodies of native tetanus toxin heavy chain, and wherein the therapeutic agent is for reduction of neuronal damage after ischemia/reperfusion or is for promotion of neuronal growth after damage, and wherein the therapeutic agent is a polypeptide.
2. The composition of claim 1 , wherein the translocation domain is further a non-aggregating translocation domain as measured by size in physiological buffers.
3. The composition of claim 1 , wherein the translocation domain is a non-aggregating translocation domain as measured by its size in physiological buffer and wherein the therapeutic agent is for reduction of neuronal damage after ischemia/reperfusion or is for promotion of neuronal growth after damage.
4. The composition of claim 1 , wherein the therapeutic agent is chemically bound to said delivery polypeptide.
5. The composition of claim 1 wherein the therapeutic agent is linked to a translocation domain of said delivery polypeptide.
6. The composition of claim 1 wherein the therapeutic agent is an enzyme, growth factor, protein or peptide.
7. The composition of claim 1 wherein the therapeutic agent is produced as a fusion protein by recombinant technology methods.
8. A composition comprising a therapeutic agent linked to a delivery polypeptide, SEQ ID NO. 12, wherein the delivery polypeptide is for delivery of a therapeutic agent to a neuronal cell, said delivery polypeptide comprising:
a binding domain that binds to the neuronal cell and comprises a hybrid of a botulinum H C domian and a tetanus H C domain, and
a translocation domain comprising an H N domain of a diphtheria toxin that translocates the therapeutic agent into the neuronal cell,
wherein the delivery polypeptide has the binding specificity of tetanus toxin and reduced affinity to neutralizing antibodies to tetanus toxin compared with the affinity to such antibodies of native tetanus toxin heavy chain, and wherein the therapeutic agent is for reduction of neuronal damage after ischemia/reperfusion oris for promotion of neuronal growth after damage, and is selected from superoxide dismutase and glutamine synthetase.